Patents by Inventor Priscille Brodin
Priscille Brodin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230233483Abstract: The disclosure relates to the use of clofoctol in the prevention or treatment of a disease caused by a coronavirus, in particular Covid-19.Type: ApplicationFiled: June 8, 2021Publication date: July 27, 2023Applicants: Apteeus, Universite De Lille, Centre National De La Recherche Scientifique, Institut National De La Sante Et De La Recherche Medicale, Centre Hospitalier Universitaire De LilleInventors: Terence Beghyn, BenoƮt Deprez, Sandrine Belouzard, Priscille Brodin
-
Publication number: 20220062326Abstract: Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-#-cyclodextrins (p?CD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, p?CD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty p?CD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. p?CD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, p?CD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence.Type: ApplicationFiled: February 20, 2020Publication date: March 3, 2022Inventors: Priscille BRODIN, Alain BOULARD, Ruxandra GREF, Arnaud MACHELART
-
Patent number: 10174050Abstract: The present invention concerns a spiroisoxazoline compound of general formula (I): in which m and n are 0 or 1, R1 represents, inter alia, an optionally substituted alkyl chain, in particular substituted with fluorine or with a cyclic group, and R2 is chosen from phenyl and optionally substituted benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the heterocycles having 5 or 6 vertices comprising at least one atom chosen from S, N and O. The present invention also concerns the use of this compound as a drug, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: GrantFiled: December 20, 2013Date of Patent: January 8, 2019Assignee: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Matthieu Frederik Desroses, Laurence Agouridas-Dutot
-
Patent number: 9957249Abstract: The present invention concerns a compound of general formula (I): in which n=0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from optionally substituted phenyl and benzyl, wherein the heterocycles having 6 vertices comprise one, two or three nitrogen atoms. The present invention also concerns the use of this compound as a medicament, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: GrantFiled: December 20, 2013Date of Patent: May 1, 2018Assignee: UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Marion Flipo, Lucie Maingot
-
Patent number: 9920042Abstract: The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections. The present invention also concerns pharmaceutical compositions comprising, as the active ingredient, at least one of the abovementioned compounds and optionally an antibiotic activatable via the EthA pathway.Type: GrantFiled: September 27, 2013Date of Patent: March 20, 2018Assignee: UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Olivier Sperando, Vincent Villeret, Baptiste Villemagne
-
Publication number: 20150344498Abstract: The present invention concerns a spiroisoxazoline compound of general formula (I): in which m and n are 0 or 1, R1 represents, inter alia, an optionally substituted alkyl chain, in particular substituted with fluorine or with a cyclic group, and R2 is chosen from phenyl and optionally substituted benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the heterocycles having 5 or 6 vertices comprising at least one atom chosen from S, N and O. The present invention also concerns the use of this compound as a drug, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: ApplicationFiled: December 20, 2013Publication date: December 3, 2015Applicant: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Matthieu Frederik Desroses, Laurence Agouridas-Dutot
-
Publication number: 20150307471Abstract: The present invention concerns a compound of general formula (I): in which n=0 or 1, R1 represents an optionally substituted alkyl chain, in particular substituted alkyl chain, in particular substituted with fluorine, X is chosen from N and CH, and R2 is chosen from optionally substituted phenyl and benzyl, wherein the heterocycles having 6 vertices comprise one, two or three nitrogen atoms. The present invention also concerns the use of this compound as a medicament, in particular in the treatment of bacterial and mycobacterial infections such as tuberculosis in combination with an antibiotic that is active against bacteria and/or mycobacteria, said compound potentiating the activity of said antibiotic.Type: ApplicationFiled: December 20, 2013Publication date: October 29, 2015Applicant: Universite de Droit et de la Sante de Lille 2Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille BRODIN, Marion FLIPO
-
Publication number: 20150225388Abstract: The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections.Type: ApplicationFiled: September 27, 2013Publication date: August 13, 2015Inventors: Nicolas Willand, Benoit Deprez, Alain Baulard, Priscille Brodin, Olivier Sperando, Vincent Villeret, Baptiste Villemagne
-
Publication number: 20150018543Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: ApplicationFiled: April 28, 2014Publication date: January 15, 2015Applicants: Institut Pasteur Korea, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Priscille BRODIN, Thierry CHRISTOPHE, Zaesung NO, Jaeseung KIM, Auguste GENOVESIO, Denis Philippe Cedric FENISTEIN, Heekyoung JEON, Fanny Anne EWANN, Sunhee KANG, Saeyeon LEE, Min Jung SEO, Eunjung PARK, Monica CONTRERAS DOMINGUEZ, Ji Youn NAM, Eun Hye KIM
-
Patent number: 8865734Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: GrantFiled: March 18, 2011Date of Patent: October 21, 2014Assignees: Institut Pasteur Korea, Institut National de la Sante et de la RechInventors: Zaesung No, Jaeseung Kim, Priscille Brodin, Min Jung Seo, Young Mi Kim, Jonathan Cechetto, Heekyoung Jeon, Auguste Genovesio, Saeyeon Lee, Sunhee Kang, Fanny Anne Ewann, Ji Youn Nam, Thierry Christophe, Denis Philippe Cedric Fenistein, Jamung Heo, Jang Jiyeon
-
Patent number: 8785452Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: GrantFiled: June 17, 2009Date of Patent: July 22, 2014Assignees: Institut National de la Sante et de la Recherche Medicale, Institut Pasteur KoreaInventors: Priscille Brodin, Thierry Christophe, Zaesung No, Jaeseung Kim, Auguste Genovesio, Denis Philippe Cedric Fenistein, Heekyoung Jeon, Fanny Anne Ewann, Sunhee Kang, Saeyeon Lee, Min Jung Seo, Eunjung Park, Monica Contreras Dominguez, Ji Youn Nam, Eun Hye Kim
-
Patent number: 8747866Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.Type: GrantFiled: September 21, 2010Date of Patent: June 10, 2014Assignee: Institut PasteurInventors: Stewart Cole, Alexander S. Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude LeClerc
-
Patent number: 8398991Abstract: A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Y51, Q55, Q56, N66, M83, V90, M93, or F94 in SEQ ID NO:1; or at least one mutation at Q3, F7 A13, L27, W42, G44, Y50, Q54, N65, N67, M82, V89, M92, or F93 in SEQ ID NO:2, or a deletion at the terminal end of less than 20 amino acids. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, AI4R, L28A, L29S, W43R, G45T, Q55I, Q56A, N66I, N67A, M83I, V90R, M93T, or F94Q in SEQ ID NO:1, and Q3L, F7I, A13R, L27A, L28S, W42R, Q44T, Q54I, N65I, M82I, V89R, M92T, and F93Q in SEQ ID NO:2. Similarly, the genetically modified strain may also secrete ESAT-6 with a hexa-histidine tag, tetra-cysteine tag, or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.Type: GrantFiled: June 20, 2006Date of Patent: March 19, 2013Assignees: Institut Pasteur, Institut Nationale de la Sante et de la Recherche MedicaleInventors: Roland Brosch, Priscille Brodin, Stewart Cole, Laleh Majlessi, Claude Leclerc
-
Publication number: 20130065884Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: ApplicationFiled: March 18, 2011Publication date: March 14, 2013Inventors: Zaesung No, Jaeseung Kim, Priscille Brodin, Min Jung Seo, Young Mi Kim, Jonathan Cechetto, Heekyoung Jeon, Auguste Genovesio, Saeyeon Lee, Sunhee Kang, Fanny Anne Ewann, Ji Youn Nam, Thierry Christophe, Denis Philippe Cedric Fenistein, Heo Jamung, Jang Jiyeon
-
Publication number: 20130012506Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: ApplicationFiled: January 13, 2011Publication date: January 10, 2013Inventors: Zaesung No, Jaeseung Kim, Priscille Brodin, Min Jung Seo, Eunjung Park, Jonathan Cechetto, Heekyoung Jeon, EunHye Kim, Jamung Heo, Ji Youn Nam, Denis Philippe Cedric Fenistein, Thierry Christophe, Monica Contreras Dominguez, Auguste Genovesio, Saeyeon Lee, Sunhee Kang, Fanny Anne Ewann
-
Publication number: 20120189662Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M. bovis BCG::RD1 or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.Type: ApplicationFiled: September 21, 2010Publication date: July 26, 2012Inventors: Stewart Cole, Alexander S. Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude LeClerc
-
Publication number: 20110178077Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.Type: ApplicationFiled: June 17, 2009Publication date: July 21, 2011Inventors: Priscille Brodin, Thierry Christophe, Zaesung No, Jaeseung Kim, Auguste Genovesio, Denis Philippe Cedric Fenistein, Heekyoung Jeon, Fanny Anne Ewann, Sunhee Kang, Saeyeon Lee, Min Jung Seo, Eunjung Park, Monica Contreras Dominguez, Ji Youn Nam, Eun Hye Kim
-
Patent number: 7883712Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.Type: GrantFiled: April 1, 2003Date of Patent: February 8, 2011Assignee: Institut PasteurInventors: Stewart Cole, Alexander S. Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude Leclerc
-
Publication number: 20070009547Abstract: A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Q55, Q56, N66, M83, V90, M93, or F94. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, A14R, L28A, L29S, W43R, G45T, Y51, Q55I, Q56A, N66I, N66A, M83I, V90R, M93T, or F94Q. Similarly, the genetically modified strain may also secrete ESAT-6 with a a histidine tag, tetra-cysteine tag or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.Type: ApplicationFiled: June 20, 2006Publication date: January 11, 2007Inventors: Roland Brosch, Priscille Brodin, Stewart Cole, Laleh Majlessi, Claude Leclerc
-
Publication number: 20050220811Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.Type: ApplicationFiled: April 1, 2003Publication date: October 6, 2005Inventors: Stewart Cole, Alexander Pym, Roland Brosch, Priscille Brodin, Laleh Majlessi, Caroline Demangel, Claude Leclerc